Table 5 Pathway enrichment analysis of co-DEGs among COVID-19, AMI and AIS (CES)
ID | Description | p.adjust | geneID |
|---|---|---|---|
hsa04640 | Hematopoietic cell lineage | 0.010279082 | 7850/1604/4311/2209/3684 |
hsa05146 | Amoebiasis | 0.010279082 | 7850/7097/383/3684/7099 |
hsa05152 | Tuberculosis | 0.011102111 | 7097/2207/26253/2209/3684/7099 |
hsa05202 | Transcriptional misregulation in cancer | 0.01214225 | 7850/1647/597/4318/2209/3684 |
hsa05140 | Leishmaniasis | 0.015823732 | 7097/2209/3684/7099 |
hsa04613 | Neutrophil extracellular trap formation | 0.055315762 | 7097/2358/2209/3684/7099 |
hsa05134 | Legionellosis | 0.055315762 | 7097/3684/7099 |
hsa05221 | Acute myeloid leukemia | 0.084037187 | 597/2209/3684 |
hsa04145 | Phagosome | 0.119488133 | 7097/2209/3684/7099 |
hsa05161 | Hepatitis B | 0.122523639 | 7097/9586/4318/7099 |
hsa05215 | Prostate cancer | 0.158636996 | 7850/9586/4318 |
hsa05150 | Staphylococcus aureus infection | 0.158636996 | 2358/2209/3684 |
hsa04064 | NF-kappa B signaling pathway | 0.158636996 | 1647/597/7099 |
hsa04625 | C-type lectin receptor signaling pathway | 0.158636996 | 338,339/2207/26253 |
hsa05144 | Malaria | 0.25395003 | 7097/7099 |
hsa04915 | Estrogen signaling pathway | 0.289515945 | 9586/4318/2289 |
hsa00561 | Glycerolipid metabolism | 0.34307639 | 84,649/2713 |
hsa05321 | Inflammatory bowel disease | 0.34307639 | 7097/7099 |
hsa04664 | Fc epsilon RI signaling pathway | 0.34307639 | 9846/2207 |
hsa04924 | Renin secretion | 0.34307639 | 3759/154 |